PURPOSE: Women with breast cancer that initially involves local lymph nodes have a higher risk for local recurrence or developing metastases. Recent data suggest that germline polymorphism is a significant, previously unrecognized factor in breast cancer progression and metastasis. We assessed the influence of 16 selected common germline polymorphisms in disease-free survival and overall survival among 216 women diagnosed with lymph node-positive breast cancer. RESULTS: The rare allele of FAS 1377G>A was significantly associated with prolonged disease-free survival (P = 0.012, risk ratio of recurrence (RR) = 0.557, 95% confidence interval (CI) = 0.353-0.878) in univariate analysis. After adjusting for known breast cancer prognostic factors the association remained significant (P = 0.050, RR = 0.500, CI = 0.309-0.809). In overall survival analysis we found a significant association of the FAS 1377G>A (P = 0.040, RR = 0.451, CI = 0.496-1.188) and IL10 592C>A polymorphisms (P = 0.020, RR = 1.707, CI = 1.087-2.680) in the univariate Cox regression. The effect remained statistically significant in the multivariate analysis for the IL10 592C>A polymorphism (P = 0.013, RR 1.841, CI 1.140-2.973). No association was found for MTHFR 677C>T, VEGF 936C>T, CCND1 870G>A, TGFB1 29T>C, FASLG 844C>T, FAS 670A>G, GPB3 825C>T, ITGA2 807C>T, ITGA2 1648G>A, ITGB3 176T>C, MMP1 -1607 1G/2G, MMP3 5A/6A, PTGS2 8473T>C, IL10 592C>A and SULT1A1 638G>A polymorphisms and disease-free survival or overall survival. CONCLUSIONS: Our data suggest that the FAS 1377G>A and IL10 592C>A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.
PURPOSE:Women with breast cancer that initially involves local lymph nodes have a higher risk for local recurrence or developing metastases. Recent data suggest that germline polymorphism is a significant, previously unrecognized factor in breast cancer progression and metastasis. We assessed the influence of 16 selected common germline polymorphisms in disease-free survival and overall survival among 216 women diagnosed with lymph node-positive breast cancer. RESULTS: The rare allele of FAS 1377G>A was significantly associated with prolonged disease-free survival (P = 0.012, risk ratio of recurrence (RR) = 0.557, 95% confidence interval (CI) = 0.353-0.878) in univariate analysis. After adjusting for known breast cancer prognostic factors the association remained significant (P = 0.050, RR = 0.500, CI = 0.309-0.809). In overall survival analysis we found a significant association of the FAS 1377G>A (P = 0.040, RR = 0.451, CI = 0.496-1.188) and IL10 592C>A polymorphisms (P = 0.020, RR = 1.707, CI = 1.087-2.680) in the univariate Cox regression. The effect remained statistically significant in the multivariate analysis for the IL10 592C>A polymorphism (P = 0.013, RR 1.841, CI 1.140-2.973). No association was found for MTHFR 677C>T, VEGF 936C>T, CCND1 870G>A, TGFB1 29T>C, FASLG 844C>T, FAS 670A>G, GPB3 825C>T, ITGA2 807C>T, ITGA2 1648G>A, ITGB3 176T>C, MMP1 -1607 1G/2G, MMP3 5A/6A, PTGS2 8473T>C, IL10 592C>A and SULT1A1 638G>A polymorphisms and disease-free survival or overall survival. CONCLUSIONS: Our data suggest that the FAS 1377G>A and IL10 592C>A polymorphisms could modify disease-free and overall survival in women with lymph node-positive breast cancer.
Authors: Loïc Le Marchand; Christopher A Haiman; David van den Berg; Lynne R Wilkens; Laurence N Kolonel; Brian E Henderson Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-03 Impact factor: 4.254
Authors: Uwe Langsenlehner; Babak Yazdani-Biuki; Tanja Eder; Wilfried Renner; Thomas C Wascher; Bernhard Paulweber; Werner Weitzer; Hellmut Samonigg; Peter Krippl Journal: Clin Cancer Res Date: 2006-02-15 Impact factor: 12.531
Authors: T Lifsted; T Le Voyer; M Williams; W Muller; A Klein-Szanto; K H Buetow; K W Hunter Journal: Int J Cancer Date: 1998-08-12 Impact factor: 7.396
Authors: Kathryn Sibley; Sara Rollinson; James M Allan; Alexandra G Smith; Graham R Law; Philippa L Roddam; Christine F Skibola; Martyn T Smith; Gareth J Morgan Journal: Cancer Res Date: 2003-08-01 Impact factor: 12.701
Authors: Eric J Jacobs; Heather Spencer Feigelson; Elizabeth B Bain; Kerri A Brady; Carmen Rodriguez; Victoria L Stevens; Alpa V Patel; Michael J Thun; Eugenia E Calle Journal: Breast Cancer Res Date: 2006-04-13 Impact factor: 6.466
Authors: Martha L Slattery; Jennifer S Herrick; Gabriella Torres-Mejia; Esther M John; Anna R Giuliano; Lisa M Hines; Mariana C Stern; Kathy B Baumgartner; Angela P Presson; Roger K Wolff Journal: Carcinogenesis Date: 2014-03-26 Impact factor: 4.944
Authors: Hongliang Liu; Qingyi Wei; Jeffrey E Gershenwald; Victor G Prieto; Jeffrey E Lee; Madeleine Duvic; Elizabeth A Grimm; Li-E Wang Journal: Melanoma Res Date: 2012-04 Impact factor: 3.599
Authors: Olga V Saik; Vadim V Nimaev; Dilovarkhuja B Usmonov; Pavel S Demenkov; Timofey V Ivanisenko; Inna N Lavrik; Vladimir A Ivanisenko Journal: BMC Med Genomics Date: 2019-03-13 Impact factor: 3.063